Disclosure: This site may earn affiliate commissions when you click provider links. This doesn't affect our recommendations. Learn more
Most people regain significant weight after stopping semaglutide or tirzepatide. Here's why it happens, how fast, and what you can do about it.
If you've been on semaglutide or tirzepatide and are thinking about stopping, or you've already stopped and the scale is moving in the wrong direction, you're not imagining things. Weight regain after GLP-1 discontinuation is not a willpower problem. It is a predictable biological consequence of how these drugs work.
Understanding that distinction matters. It changes how you plan, what support you look for, and whether long-term treatment makes sense for you.
GLP-1 receptor agonists work by mimicking a gut hormone that regulates appetite, slows gastric emptying, and damps the constant low-level hunger signals that most people with obesity experience. Patients often describe going from food constantly occupying their thoughts to simply not thinking about it much — clinicians sometimes call this reduction in "food noise."
The drug doesn't rewire your brain permanently. When you stop taking it, those hormonal signals return to their prior state. Your appetite comes back, often forcefully, because the body has defended a higher weight set point for years. The medication suppressed that set point temporarily. Stopping it removes the suppression.
Compounding the issue: significant weight loss itself slows your resting metabolic rate and reduces lean muscle mass. When appetite rebounds after stopping, you're eating at pre-loss levels but burning fewer calories than before you started. That combination accelerates regain.
Dr. Joshua Neal, a physician specializing in diabetes, metabolism, and endocrinology at MUSC, puts it plainly: most of what drives overall food consumption is biologically driven by hormonal signaling — not conscious choices (MUSC Health, 2026).
Faster than most people expect.
A large meta-analysis covering 37 studies and more than 9,300 participants found that people who stopped semaglutide or tirzepatide regained an average of nearly 10 kilograms within the first year. The monthly regain rate for newer GLP-1 agents was approximately 0.8 kg per month (TCTMD, 2026). At that rate, meaningful regain is noticeable within two to three months.
The same analysis estimated that patients who stopped semaglutide or tirzepatide would return to their pre-treatment weight within approximately 1.5 years — compared to 1.7 years across all weight-loss medications combined.
A separate systematic review found similar patterns across multiple trials. In one representative trial included in the analysis, participants who discontinued semaglutide after achieving weight loss of roughly 17% regained about two-thirds of that loss within the following year (PMC, 2024). Those who continued on medication maintained or extended their results.
These aren't outlier numbers. They're consistent across studies.
The cardiometabolic benefits of GLP-1 therapy also reverse with the weight.
The meta-analysis found that systolic blood pressure increased at roughly 0.5 mmHg per month after stopping. Fasting glucose, HbA1c, and triglycerides all trended back toward baseline levels — in most cases normalizing within one to one and a half years of discontinuation (TCTMD, 2026).
For people who started GLP-1 therapy partly because of prediabetes, elevated cardiovascular risk, or hypertension, this matters a lot. The weight regain and the metabolic regression tend to move together.
Answer 5 questions to see which GLP-1 providers are built for where you are now.
Take the free quiz →There are plenty of legitimate reasons to discontinue GLP-1 therapy, and the decision isn't simple for most people.
Cost. Brand-name Wegovy and Zepbound can run $500–$1,000 per month without insurance. Compounded semaglutide — which uses the same active ingredient but is not FDA-approved as a finished drug product — has been more affordable, but the FDA has signaled it may restrict availability as the branded shortage designation changes. If the math doesn't work, it doesn't work.
Side effects. Nausea, vomiting, and GI discomfort are the most common reasons people stop early, particularly in the first weeks at a new dose. Some people find these manageable; others don't. That's a personal medical decision.
Pregnancy or planning to become pregnant. GLP-1 medications are generally not recommended during pregnancy. Women who are planning to conceive are typically advised to stop before trying.
Shortage or supply interruption. Access has been uneven, and some people have been forced off their medication by supply issues rather than choice.
Personal preference. Some people use GLP-1 therapy as a bridge to a lower weight, build habits during that window, and intentionally plan a transition off. That's a valid strategy, though one that requires preparation.
Whatever the reason, stopping is not a failure. The biology of regain is real regardless.
If you're planning to stop — or are on a forced break due to supply issues — there are things you can do to slow regain.
Taper rather than stop abruptly. Some clinicians recommend stepping down the dose gradually rather than stopping cold, on the theory that a slower taper gives your body more time to adjust. Talk to your prescriber about whether a tapering schedule makes sense for your situation.
Build the habits before you stop. The window while you're on medication is the easiest time to build new eating patterns, because hunger is suppressed. Meal composition (higher protein, structured eating windows), portion habits, and movement routines are all easier to establish when you're not fighting intense hunger. The goal isn't to "earn" stopping — it's to give yourself a foundation to work from after you do.
Prioritize resistance training. Weight loss on GLP-1 therapy includes lean muscle loss, not just fat. Resistance training during treatment reduces how much muscle you lose, and continuing after you stop helps preserve metabolic rate. This is one of the most evidence-backed strategies for maintaining weight loss in general (PMC, 2024).
Weigh yourself consistently. Early regain is easier to address than regain you don't notice until it's significant. Daily weigh-ins at the same time — not to obsess over day-to-day fluctuations, but to see the trend before small gains compound — gives you the data to act (MUSC Health, 2026).
Stay connected to clinical support. Going it alone after stopping is harder than having a clinician or behavioral coach tracking with you. Several programs are specifically designed for the maintenance phase.
The framing of GLP-1 therapy as a short course — take it, lose the weight, stop — doesn't match what the evidence shows about how obesity works.
A growing number of obesity medicine specialists now view GLP-1 agonists the way they view blood pressure or cholesterol medications: as chronic treatments for a chronic condition. The PMC systematic review put it directly: "long-term pharmacotherapy is required to maintain weight loss, and cessation or withdrawal from therapy leads to weight regain" (PMC, 2024).
That's not a pharmaceutical industry talking point. It reflects what happens in study after study when the drug is removed.
This doesn't mean everyone should stay on a GLP-1 indefinitely. Cost, access, side effect tolerance, and personal goals all factor in. But it does mean that stopping should be a deliberate decision made with clinical guidance, not an assumption that the weight loss will just hold.
If cost is the main barrier, it's worth exploring whether your current program is optimized for affordability. Some providers offer flat-rate pricing or work with insurance to reduce out-of-pocket costs significantly.
Not every telehealth program is built with ongoing maintenance in mind. The ones below prioritize clinical continuity, behavioral support, or both — which matters whether you're planning to stay on medication long-term or trying to transition off with the best chance of holding your results.
Found
Membership + medication (pricing varies by plan)
13+ medications, ongoing clinical support, and behavioral coaching — built for the full arc of treatment, not just the first few months.
Mochi Health
$178–$278/month (membership + medication, as of April 2026; prices may vary)
Flat medication pricing at every dose level, plus unlimited physician and dietitian access — designed so cost doesn't force you off a program that's working.
WeightWatchers Clinic
$74/month + medication costs (as of April 2026; prices may vary)
GLP-1 prescriptions bundled with WW's group coaching and behavioral app — one of the few programs that actively supports the habit-building that makes maintenance possible.
Pros
Cons
The honest answer for most people is that stopping GLP-1 therapy without a clear maintenance plan carries a high probability of returning to near-baseline weight within one to two years. That's not a reason to stay on a medication you can't afford or tolerate. But it is a reason to stop deliberately, with support, and with realistic expectations.
If you're unsure whether to stay on your current program, switch to one with better long-term support, or plan a structured taper, talking to a prescriber who specializes in obesity medicine is the clearest path forward. You can use the quiz above to find programs with ongoing clinical access that fit your situation.